Clifford Chance has advised Mitsubishi Corp on its acquisition of a 20 percent stake in Olam International for approximately $1.1 billion, with WongPartnership advising the issuer.

According to Reuters, Mitsubishi’s purchase of the stake in Olam is a key vote of confidence that will allow the Singapore agri-trader to exploit M&A opportunities thrown up by the slump in the global commodities market.

The deal will also help Olam, whose accounting practices were attacked in 2012 by short seller Muddy Waters before it was rescued by Singapore state investor Temasek, make greater inroads into Japan while gaining a hand in building businesses in Africa.

The Clifford Chance team was led by partners Lee Taylor and Kathy Honeywood, with partners Raymond Tong and Nish Shetty advising on the regulatory aspects of the transaction.

Meanwhile, the WongPartnership team included joint managing partner Ng Wai King, and partners Audrey Chng and James Choo. 

Olam, one of the world's leading traders in commodities such as coffee, cocoa and rice, said it picked Mitsubishi in a competitive bidding process and the firms would explore strategic partnerships. It declined to provide the names of the other bidders.

Mitsubishi, one of Japan's biggest trading houses, said the tie-up will help combine the group's processing, manufacturing and downstream business experience with Olam's extensive sustainable raw material supply platforms.

Related Articles

Haiwen, CC advise on China TCM's $2 bln take-private deal

Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.

CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO

by Charlie Wu 吴卓言 |

Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.

CC, Slaughters advise as HK-listed SciClone goes private for $1.13 bln

Clifford Chance has advised the Hong Kong-listed SciClone Pharmaceuticals on an offer to take it private by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).